{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1647","upperLimit":"2197","value":"1902"},{"groupId":"OG001","lowerLimit":"1436","upperLimit":"2009","value":"1699"},{"groupId":"OG002","lowerLimit":"1609","upperLimit":"1993","value":"1790"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"28"}],"units":"Participants"}],"description":"To determine the pharmacokinetics of selumetinib after administration of the selumetinib granule formulation","dispersionType":"95% Confidence Interval","groups":[{"description":"Global Cohort 1 (\\>=4 to \\<7 years)","id":"OG000","title":"Global Cohort 1"},{"description":"Global Cohort 2 (\\>=1 to \\<4 years)","id":"OG001","title":"Global Cohort 2"},{"description":"Global Cohorts (\\>=1 to \\<7 years)","id":"OG002","title":"Total in Global"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic analysis set was used for analysis. Japan Cohort was not considered for the primary endpoint analysis. Some records were excluded for given visits and analytes due to missing concentration data, issues taking the medication and usage of prohibited medications.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1, 2, 3, 4, 6, 8 and 10-12 hours after selumetinib single dose on the first day of study treatment (Cycle 1 Day 1) (each cycle is 28 days)","title":"Selumetinib AUC0-12 Derived After Single Dose Administration","type":"PRIMARY","unitOfMeasure":"h*ng/mL"}